News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
744,798 Results
Type
Article (50302)
Company Profile (384)
Press Release (694112)
Section
Business (218291)
Career Advice (2566)
Deals (37705)
Drug Delivery (113)
Drug Development (85446)
Employer Resources (179)
FDA (17019)
Job Trends (16205)
News (368815)
Policy (35421)
Tag
Academia (2859)
Alliances (54024)
Alzheimer's disease (1375)
Approvals (16961)
Artificial intelligence (192)
Bankruptcy (376)
Best Places to Work (12283)
Biotechnology (249)
Breast cancer (214)
Cancer (1606)
Cardiovascular disease (134)
Career advice (2144)
CAR-T (119)
Cell therapy (342)
Clinical research (68324)
Collaboration (625)
Compensation (313)
COVID-19 (2773)
C-suite (140)
Data (1503)
Diabetes (201)
Diagnostics (6560)
Earnings (88898)
Employer resources (158)
Events (119833)
Executive appointments (515)
FDA (17819)
Funding (546)
Gene therapy (239)
GLP-1 (713)
Government (4790)
Healthcare (20107)
Infectious disease (2879)
Inflammatory bowel disease (124)
Interviews (443)
IPO (17064)
Job creations (4368)
Job search strategy (1818)
Layoffs (479)
Legal (8746)
Lung cancer (237)
Manufacturing (241)
Medical device (13936)
Medtech (13941)
Mergers & acquisitions (20889)
Metabolic disorders (555)
Neuroscience (1775)
NextGen: Class of 2025 (7144)
Non-profit (4902)
Northern California (1910)
Obesity (318)
Opinion (238)
Patents (141)
People (60625)
Phase I (21221)
Phase II (30016)
Phase III (22539)
Pipeline (630)
Postmarket research (2755)
Preclinical (9038)
Radiopharmaceuticals (254)
Rare diseases (316)
Real estate (6628)
Regulatory (23560)
Research institute (2559)
Resumes & cover letters (416)
Southern California (1655)
Startups (3962)
United States (17424)
Vaccines (670)
Weight loss (241)
Date
Today (121)
Last 7 days (444)
Last 30 days (2047)
Last 365 days (36536)
2025 (1916)
2024 (37010)
2023 (41919)
2022 (53287)
2021 (57910)
2020 (56655)
2019 (49913)
2018 (37839)
2017 (34746)
2016 (34737)
2015 (40811)
2014 (34506)
2013 (29574)
2012 (31619)
2011 (32254)
2010 (30144)
Location
Africa (901)
Arizona (220)
Asia (42885)
Australia (6995)
California (4375)
Canada (1579)
China (377)
Colorado (202)
Connecticut (217)
Europe (94664)
Florida (619)
Georgia (150)
Illinois (457)
Indiana (255)
Maryland (722)
Massachusetts (3454)
Michigan (196)
Minnesota (334)
New Jersey (1231)
New York (1234)
North Carolina (885)
Northern California (1910)
Ohio (161)
Pennsylvania (1018)
South America (1296)
Southern California (1655)
Texas (643)
Utah (126)
Washington State (448)
744,798 Results for "par pharmaceutical inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is expanding its voluntary recall to include seven lots of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level. The product is being recalled due to the potential for the presence of silicone particulates in the product.
April 22, 2024
·
5 min read
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution
Endo International plc announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), is voluntarily recalling one lot of Treprostinil Injection 20mg/20mL (1mg/mL) to the consumer level.
March 12, 2024
·
4 min read
Press Releases
Bexion Pharmaceuticals, Inc. to Participate in the Jefferies London Healthcare Conference
November 12, 2024
·
2 min read
Pharm Country
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical stage pharmaceutical company, today announced that management will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.
June 20, 2024
·
2 min read
Press Releases
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
November 7, 2024
·
1 min read
Press Releases
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.
December 30, 2024
·
11 min read
Press Releases
HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
January 7, 2025
·
8 min read
Press Releases
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update
December 29, 2024
·
13 min read
Pharm Country
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that it will participate in the EF Hutton Annual Global Conference, which will take place on May 15, 2024, at The Plaza Hotel in New York City.
May 8, 2024
·
2 min read
Press Releases
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
October 24, 2024
·
4 min read
1 of 74,480
Next
